Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
1,037 USD +0.97% Intraday chart for Regeneron Pharmaceuticals, Inc. +3.35% +18.02%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $25,610,229, According to a Recent SEC Filing MT
Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $1,125 From $1,050 MT
RBC Capital Raises Price Target on Regeneron Pharmaceuticals to $1,229 From $1,200, Maintains Outperform Rating MT
Sanofi, Regeneron Secure US FDA Nod for Kevzara’s Use in Polyarticular Juvenile Idiopathic Arthritis MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM
Regeneron, Sanofi Gain FDA Approval for Kevzara to Treat Juvenile Idiopathic Arthritis MT
Regeneron, Sanofi Get Expanded FDA OK for Kevzara in Polyarticular Juvenile Idiopathic Arthritis DJ
Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Has Approves Kevzara® CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $798,821, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185 MT
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier MT
FibroGen To Begin Trials on Tumor Treatment After FDA OK DJ
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials CI
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee MT
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months MT
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S. DJ
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD CI
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer MT
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 CI
Chart Regeneron Pharmaceuticals, Inc.
More charts
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,037 USD
Average target price
1,047 USD
Spread / Average Target
+1.04%
Consensus
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. News Regeneron Pharmaceuticals, Inc.
  5. Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW